Filing Details

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D/A

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

Eiger BioPharmaceuticals, Inc.

(Name of Issuer)

 

Common Stock, $0.001 par value per share

(Title of Class of Securities)

 

28249U 105

(CUSIP Number)

 

Frank Kung

Vivo Capital LLC

505 Hamilton Avenue, Suite 207

Palo Alto, CA 94301

Telephone: (650) 688-0818

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

October 30, 2017

(Date of Event Which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

 

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).  

 

 

1	NAME OF REPORTING PERSON   Vivo Ventures VI, LLC
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☐
					(b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS			Not Applicable
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION			State of Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER	0
		8	SHARED VOTING POWER	1,787,091 (1)
		9	SOLE DISPOSITIVE POWER	0
		10	SHARED DISPOSITIVE POWER	1,787,091 (1)
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,787,091 (1)
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   17.5%(2)
14	TYPE OF REPORTING PERSON			OO

 

(1)

Consists of (a) 1,774,095 shares of Common Stock held by Vivo Ventures Fund VI, L.P. (“Fund VI”) and (b) 12,996 shares held by Vivo Ventures VI Affiliates Fund, L.P. (“VI Affiliates Fund”). Vivo Ventures VI, LLC is the sole general partner of each of Fund VI and VI Affiliated Fund and may be deemed to beneficially own such shares. The voting members of Vivo Ventures VI, LLC are Dr. Frank Kung, Dr. Albert Cha, and Dr. Edgar Engleman, none of whom has individual voting or investment power with respect to these shares and each of whom disclaims beneficial ownership of such shares.

(2)

This percentage is calculated based on 10,221,779 shares of Common Stock, $0.001 par value, of the Issuer outstanding after the completion of the Issuer’s offering, as disclosed in the final prospectus filed by the Issuer on October 30, 2017, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-212114). The Reporting Person’s beneficial ownership changed primarily due to an increase in the total number of shares of the Issuer’s Common Stock outstanding.

 

 

1	NAME OF REPORTING PERSON   Vivo Ventures Fund VI, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☐
					(b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS			WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION			State of Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER	0
		8	SHARED VOTING POWER	1,774,095
		9	SOLE DISPOSITIVE POWER	0
		10	SHARED DISPOSITIVE POWER	1,774,095
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	1,774,095
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   17.4%(1)
14	TYPE OF REPORTING PERSON			PN

 

(1)

This percentage is calculated based on 10,221,779 shares of Common Stock, $0.001 par value, of the Issuer outstanding after the completion of the Issuer’s offering, as disclosed in the final prospectus filed by the Issuer on October 30, 2017, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-212114). The Reporting Person’s beneficial ownership changed primarily due to an increase in the total number of shares of the Issuer’s Common Stock outstanding.

 

 

1	NAME OF REPORTING PERSON   Vivo Ventures VI Affiliates Fund, L.P.
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				(a) ☐
					(b) ☐
3	SEC USE ONLY
4	SOURCE OF FUNDS			WC
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
6	CITIZENSHIP OR PLACE OF ORGANIZATION			State of Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER	0
		8	SHARED VOTING POWER	12,996
		9	SOLE DISPOSITIVE POWER	0
		10	SHARED DISPOSITIVE POWER	12,996
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	12,996
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES   ☐
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)   0.1%(1)
14	TYPE OF REPORTING PERSON			PN

 

(1)

This percentage is calculated based on 10,221,779 shares of Common Stock, $0.001 par value, of the Issuer outstanding after the completion of the Issuer’s offering, as disclosed in the final prospectus filed by the Issuer on October 30, 2017, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, which forms part of the Issuer’s Registration Statement on Form S-3 (File No. 333-212114). The Reporting Person’s beneficial ownership changed primarily due to an increase in the total number of shares of the Issuer’s Common Stock outstanding.

 

 

SCHEDULE 13D/A

 

Explanatory Note: This Amendment No. 1 (the “Amendment”), which amends and supplements the statement on Schedule 13D, filed on April 1, 2016 (the “Prior 13D”) by the Reporting Persons, relates to the common stock, par value $0.001 per share (the “Common Stock”), of Eiger BioPharmaceuticals, Inc., a Delaware corporation (the “Issuer”). The principal executive offices of the Issuer are located at 350 Cambridge Avenue, Suite 350, Palo Alto, CA 94306.

 

The purpose of this Amendment is to report changes in the Reporting Persons’ beneficial ownerships of the Issuer’s Common Stock, which resulted primarily due to increases in the total number of shares of the Issuer’s Common Stock outstanding. Except as specifically provided herein, this Amendment does not modify any of the information previously reported on the Prior 13D. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Prior 13D.

 

Item 4. Purpose of Transaction

 

Vivo Ventures Fund VI, L.P. purchased 186,136 shares of Common Stock on August 18, 2016.

 

Vivo Ventures VI Affiliates Fund, L.P. purchased 1,364 shares of Common Stock on August 18, 2016.

 

Item 5. Interest in Securities of the Issuer

 

(a)            The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment.

 

(b)            The information requested by this paragraph is incorporated herein by reference to the information provided on the cover pages to this Amendment.

 

(c)            Except as disclosed herein, none of the Reporting Persons or their affiliates has effected any other transactions in the securities of the Issuer during the past 60 days.

 

(d)            Not applicable.

 

(e)            Not applicable.

 

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

 

November 1, 2017	VIVO VENTURES VI, LLC
	By:	/s/ Frank Kung
		Frank Kung Managing Member

 

	VIVO VENTURES FUND VI, L.P.
	By: Vivo Ventures VI, LLC Its: General Partner
	By:	/s/ Frank Kung
		Frank Kung Managing Member

  

	VIVO VENTURES VI AFFILIATES FUND, L.P.
	By: Vivo Ventures VI, LLC Its: General Partner
	By:	/s/ Frank kung
		Frank Kung Managing Member